Medicines agency sets out plan to ensure its work keeps pace with the state-of-the-art
The European Medicines Agency has detailed how it hopes to work more closely with researchers in the coming years, particularly on emerging technologies that hold promise in drug development.
In an update of its five-year strategy, published on 31 March, the agency said it wants to boost its work with researchers who identify disease markers. It wants to encourage them to get these indicators externally validated so they can be used in clinical trials of new drugs.